Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus pevonedistat versus azacitidine in older/unfit newly diagnosed AML
2019-001323-12Phase 3Completed
- Sponsor
- Fundación PETHEMA
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Azacitidine plus pevonedistat with Azacitidine monotherapy (2 arms). Primary endpoint: Overall survival. Started Apr 2020; status: completed.
02
Drugs
pevonedistatazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-001323-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001323-12.